Form 13-F position report

UNUM THERAPEUTICS INC

Reported by TCG Crossover Management LLC

COGT CUSIP 19240Q201 Manager CIK 0001839948

Reported 4,946,894 shares, down 921,268 (15.7%) from the prior quarter.

Reported value -8.7%; share count -15.7% vs. the prior quarter.

Reduced
% of reported 13F value 5.45% This manager · Q1 2026
Shares 4,946,894 Quarter-end amount reported
Reported value $190,405,950 Fair value at quarter end
Consecutive quarters held 18 Through Q1 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 23595000
2022-03-31 22328000
2022-06-30 31399000
2022-09-30 51937000
2022-12-31 41974846
2023-03-31 39178943
2023-06-30 66671537
2023-09-30 54902659
2023-12-31 33110527
2024-03-31 41760600
2024-06-30 58709681
2024-09-30 75215250
2024-12-31 54322125
2025-03-31 41716606
2025-06-30 50004213
2025-09-30 97621606
2025-12-31 208437114
2026-03-31 190405950
2026-06-30 187866673
2026-09-30 80050096

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for UNUM THERAPEUTICS INC held by TCG Crossover Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 2,500,003 -2,354,433 (-48.5%) 2.26% $80,050,096 2026-11-16
Q2 2026 Reduced 4,854,436 -92,458 (-1.9%) 4.52% $187,866,673 2026-08-14
Q1 2026 Reduced 4,946,894 -921,268 (-15.7%) 5.45% $190,405,950 2026-05-15
Q4 2025 Reduced 5,868,162 -930,000 (-13.7%) 6.9% $208,437,114 2026-02-17
Q3 2025 Reduced 6,798,162 -166,213 (-2.4%) 4.8% $97,621,606 2025-11-17
Q2 2025 Unchanged 6,964,375 0 (0.0%) 5.71% $50,004,213 2025-08-14
Q1 2025 Unchanged 6,964,375 0 (0.0%) 5.69% $41,716,606 2025-05-14
Q4 2024 Unchanged 6,964,375 0 (0.0%) 5.31% $54,322,125 2025-02-14
Q3 2024 Unchanged 6,964,375 0 (0.0%) 6.37% $75,215,250 2024-11-14
Q2 2024 Added 6,964,375 +750,000 (12.1%) 6.12% $58,709,681 2024-08-14
Q1 2024 Added 6,214,375 +583,333 (10.4%) 3.3% $41,760,600 2024-05-15
Q4 2023 Unchanged 5,631,042 0 (0.0%) 3.67% $33,110,527 2024-02-14
Q3 2023 Unchanged 5,631,042 0 (0.0%) 8.08% $54,902,659 2023-11-14
Q2 2023 Added 5,631,042 +2,000,000 (55.1%) 10.93% $66,671,537 2023-08-14
Q1 2023 Unchanged 3,631,042 0 (0.0%) 7.64% $39,178,943 2023-05-15
Q4 2022 Added 3,631,042 +150,000 (4.3%) 7.41% $41,974,846 2023-02-14
Q3 2022 Unchanged 3,481,042 0 (0.0%) 15.58% $51,937,000 2022-11-14
Q2 2022 Added 3,481,042 +500,000 (16.8%) 13.34% $31,399,000 2022-08-15
Q1 2022 Added 2,981,042 +231,005 (8.4%) 8.96% $22,328,000 2022-05-16
Q4 2021 New 2,750,037 +2,750,037 (0.0%) 11.05% $23,595,000 2022-02-18

Who else reported the position

344 managers reported UNUM THERAPEUTICS INC for Q1 2026.

Managers reporting UNUM THERAPEUTICS INC in Q1 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 23,122,748 +35,781 0.05% $889,994,587 18 qtrs
BlackRock Inc Added 16,045,014 +3,070,423 0.01% $617,572,589 7 qtrs
DEERFIELD MANAGEMENT COMPANY L P SERIES C Unchanged 9,043,903 0 4.11% $348,099,826 22 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC New 7,333,333 +7,333,333 0.01% $282,259,987 1 qtr
VANGUARD CAPITAL MANAGEMENT LLC New 6,894,959 +6,894,959 < 0.01% $265,386,972 1 qtr
JANUS HENDERSON GROUP PLC Added 5,965,125 +1,427,717 0.11% $229,633,788 22 qtrs
STATE STREET CORPORATION Added 5,663,543 +723,243 < 0.01% $217,989,770 22 qtrs
Fairmount Funds Management LLC Reduced 5,503,418 -3,500,000 15.3% $211,826,559 22 qtrs
RTW INVESTMENTS LP Reduced 5,458,675 -2,133,566 2.09% $210,104,401 3 qtrs
TCG Crossover Management LLC This report Reduced 4,946,894 -921,268 5.45% $190,405,950 18 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2026
Filed
May 15, 2026
Filing type
13F-HR
Position type
COMM

Voting authority reported

Sole
4,946,894
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.